PNEUMATIC RETINOPEXY FOR GIANT RETINAL TEAR ASSOCIATED RETINAL DETACHMENT: A Retrospective Cohort Study

医学 四分位间距 视网膜脱离 回顾性队列研究 视网膜 眼科 视力 眼泪 外科 队列 玻璃体切除术 内科学
作者
Miguel Cruz-Pimentel,Mohammed Alfalah,Wei Wei Lee,Isabela Martins Melo,Jovi C. Y. Wong,Neda Pirouzmand,Aurora Pecaku,Sueellen Demian,Faryal Maniyali,Peter J. Kertes,Rajeev H. Muni
出处
期刊:Retina-the Journal of Retinal and Vitreous Diseases [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1097/iae.0000000000004344
摘要

Purpose: To report the technique and long-term outcomes of patients with giant retinal tear associated retinal detachment (GRT-RD) treated with pneumatic retinopexy (PnR). Methods: Retrospective cohort study. All patients presenting with GRT-RD with tears in the superior ten-clock hours who underwent primary PnR were included in this study. Results: 31 patients were included in the study. 61.2% (19/31) achieved PARR with PnR at 3 months and 58.0% (18/31) at the final follow-up. Patients included in this study had a median follow-up of 24 months (interquartile range 46.5). The absence of retinal tears elsewhere at baseline was associated with a final PARR of 80% (16/20) (p= 0.007). Thirteen eyes required PPV after a failed PnR. Two eyes required the intraoperative use of perfluorocarbon liquids (PFCL). No eyes required silicone oil (SO). Visual acuity improved significantly from baseline to the last follow-up. Final anatomic reattachment rate was 100% (31/31). Conclusion: For selected cases of GRT-RDs affecting the superior ten-clock hours, PnR could be a possible treatment option when patients consent to extra visits and the surgeon has substantial expertise. When lacking this extensive experience and comfort with PnR, PPV remains the treatment that is most likely to result in a primary anatomic reattachment. While this study provides guidance on PnR technique for GRT-RDs, it is essential to note that the reported PARR may be contingent on the expertise of the surgeon/center, and the authors recommend that those new to PnR first gain substantial experience in cases meeting clinical trial criteria.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爆米花应助凶凶采纳,获得10
刚刚
科研通AI5应助科研通管家采纳,获得10
刚刚
完美世界应助科研通管家采纳,获得10
刚刚
1秒前
Owen应助科研通管家采纳,获得10
1秒前
CipherSage应助科研通管家采纳,获得10
1秒前
Hello应助科研通管家采纳,获得10
1秒前
Jasper应助科研通管家采纳,获得30
1秒前
丘比特应助科研通管家采纳,获得10
1秒前
情怀应助科研通管家采纳,获得10
1秒前
123657应助科研通管家采纳,获得10
1秒前
嘤嘤怪应助科研通管家采纳,获得10
1秒前
bkagyin应助乌兰巴托没有海采纳,获得10
1秒前
喜悦中道应助科研通管家采纳,获得10
1秒前
嘤嘤怪应助科研通管家采纳,获得10
1秒前
1秒前
星辰大海应助科研通管家采纳,获得10
2秒前
zzzq应助科研通管家采纳,获得10
2秒前
隐形曼青应助科研通管家采纳,获得10
2秒前
wanci应助科研通管家采纳,获得10
2秒前
李健应助科研通管家采纳,获得10
2秒前
852应助科研通管家采纳,获得10
2秒前
2秒前
搜集达人应助科研通管家采纳,获得10
2秒前
嘤嘤怪应助科研通管家采纳,获得10
2秒前
2秒前
田様应助科研通管家采纳,获得10
2秒前
2秒前
科研通AI5应助科研通管家采纳,获得10
2秒前
Metrix应助科研通管家采纳,获得20
2秒前
3秒前
小杨完成签到 ,获得积分10
3秒前
从心发布了新的文献求助10
4秒前
4秒前
不安青牛应助奶昔采纳,获得10
4秒前
chao发布了新的文献求助10
4秒前
火星上的菲鹰应助wen采纳,获得10
5秒前
zyh发布了新的文献求助10
6秒前
6秒前
JamesPei应助南兮采纳,获得10
7秒前
高分求助中
Continuum Thermodynamics and Material Modelling 4000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3522709
求助须知:如何正确求助?哪些是违规求助? 3103705
关于积分的说明 9266832
捐赠科研通 2800287
什么是DOI,文献DOI怎么找? 1536901
邀请新用户注册赠送积分活动 715181
科研通“疑难数据库(出版商)”最低求助积分说明 708660